Efficacy, safety, and retention rate of extended-release divalproex versus conventional delayed-release divalproex A protocol for systematic review and meta-analysis

Background: A novel once-daily divalproex-extended release (VPA-ER) dose formulation has been developed, which prolongs therapeutic serum levels compared with that of twice-daily conventional divalproex-delayed release (VPA-DR). Currently, there is lack of meta-analysis focusing on drug retention rate between VPA-ER and VPA-DR. Thus, our study is the first one that aims to systematically examine and compare the efficacy, safety, and retention rate of VPA-ER and VPA-DR. Methods: Online databases including MEDLINE via PubMed, Cochrane Library, Embase (up to October 30, 2021) will be applied for literature screen. We will conduct meta-analysis by using Stata16.0 software. Results: This study aims to evaluate the efficacy, safety, and drug retention rate of VPA-ER versus conventional VPA-DR Conclusion: Once-daily VPA-ER may present a positive efficacy and not increase the incidence of AEs and has a higher retention rate for patients, which can be used as a substitute for conventional VPA-DR. INPLASY registration number: INPLASY2021110090 (DOI: 10.37766/inplasy2021.11.0090).